Deal Library / Pharma BD Deal Intelligence

Novo Nordisk A/S — Pharma Deals

The Pharma Closeout tracks 29 deals, $43.9B in disclosed deal value, 9 with a post-close Outcome Score for Novo Nordisk A/S.

Median Critic Score: 88  ·  Median Outcome Score: 68

Best outcome: Novo Nordisk A/S / Emisphere Technologies (90)  ·  Weakest outcome: Novo Nordisk A/S / KBP Biosciences (26)

All 29 deals

• Novo Nordisk A/S / Emisphere Technologies — 2020 · $1.4B · Worked — the deal delivered on its rationale.
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2019 · $3.3B · Worked — the deal delivered on its rationale.
• Novo Nordisk A/S / Vivtex Inc. — 2026 · $2.1B · Largely worked — most objectives met.
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Largely worked — most objectives met.
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2021 · $3.3B · Largely worked — most objectives met.
• Novo Nordisk A/S / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2026 · $2.6B · Largely worked — most objectives met.
• Novo Nordisk A/S / Inversago Pharma — 2023 · $1.1B · Largely worked — most objectives met.
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Mixed — partial payoff, real shortfalls.
• Novo Nordisk A/S / KBP Biosciences — 2023 · $1.3B · Did not work — the deal failed to deliver.
• Novo Nordisk A/S / Ablexis, LLC — 2026
• Novo Nordisk A/S / Anthropic PBC — 2026
• Novo Nordisk A/S / Nanexa AB — 2026 · $1.3B
• Novo Nordisk A/S / Kallyope Inc. — 2026
• Novo Nordisk A/S / Orbis Medicines ApS — 2026 · $1.4B
• Novo Nordisk A/S / Akero Therapeutics, Inc. — 2025 · $5.2B
• Novo Nordisk A/S / Deep Apple Therapeutics, Inc. — 2025 · $812M
• Novo Nordisk A/S / Omeros Corporation — 2025 · $2.1B
• Novo Nordisk A/S / The United Laboratories International Holdings Limited — 2025 · $2.0B
• Novo Nordisk A/S / Septerna, Inc. — 2025 · $2.2B
• Novo Nordisk A/S / Lexicon Pharmaceuticals Inc. — 2025 · $1.0B
• Novo Nordisk A/S / Neomorph Inc. — 2024 · $1.5B
• Novo Nordisk A/S / NanoVation Therapeutics, Inc. — 2024 · $600M
• Novo Nordisk A/S / Cellarity, Inc. — 2024 · $532M
• Novo Nordisk A/S / Biosplice Therapeutics, Inc. — 2024
• Novo Nordisk A/S / Metaphore Biotechnologies, Inc. — 2024 · $600M
• Novo Nordisk A/S / Omega Therapeutics, Inc. — 2023
• Novo Nordisk A/S / Aspect Biosystems Ltd. — 2023 · $2.7B
• Novo Nordisk A/S / Valo Health, Inc. — 2023 · $4.8B
• Novo Nordisk A/S / Zealand Pharma A/S — 2022

← Deal Library  ·  Interactive search  ·  How we score deals